Your browser is no longer supported. Please, upgrade your browser.
BIO [NYSE]
Bio-Rad Laboratories, Inc.
IndexS&P 500 P/E5.61 EPS (ttm)135.93 Insider Own14.34% Shs Outstand29.82M Perf Week7.95%
Market Cap21.64B Forward P/E58.43 EPS next Y13.04 Insider Trans-0.02% Shs Float21.36M Perf Month14.19%
Income4.10B PEG0.31 EPS next Q3.00 Inst Own81.00% Short Float2.82% Perf Quarter26.73%
Sales2.70B P/S8.01 EPS this Y116.60% Inst Trans-0.00% Short Ratio4.77 Perf Half Y28.87%
Book/sh355.73 P/B2.14 EPS next Y-4.35% ROA31.10% Target Price755.00 Perf Year44.65%
Cash/sh35.91 P/C21.22 EPS next 5Y17.80% ROE41.50% 52W Range472.84 - 756.64 Perf YTD30.74%
Dividend- P/FCF45.43 EPS past 5Y101.00% ROI-6.90% 52W High0.72% Beta0.84
Dividend %- Quick Ratio2.60 Sales past 5Y4.70% Gross Margin57.20% 52W Low61.18% ATR15.91
Employees8000 Current Ratio3.60 Sales Q/Q27.20% Oper. Margin15.50% RSI (14)85.98 Volatility3.20% 2.17%
OptionableYes Debt/Eq0.00 EPS Q/Q42.50% Profit Margin- Rel Volume0.98 Prev Close745.69
ShortableYes LT Debt/Eq0.00 EarningsJul 29 AMC Payout0.00% Avg Volume126.42K Price762.12
Recom1.50 SMA2010.88% SMA5018.59% SMA20026.34% Volume123,888 Change2.20%
Jan-08-20Initiated Wells Fargo Overweight $430
Jan-07-20Initiated Citigroup Buy $450
Oct-17-18Initiated Goldman Buy $350
Sep-20-18Initiated Morgan Stanley Equal-Weight $335
Feb-16-18Downgrade CL King Buy → Neutral
Jul-13-17Initiated Wells Fargo Outperform
Jun-28-17Upgrade Deutsche Bank Hold → Buy $220 → $255
Jan-18-17Initiated Deutsche Bank Hold $195
Oct-13-16Initiated CL King Buy
May-06-15Reiterated Jefferies Buy $150 → $165
Dec-18-09Initiated Maxim Group Buy $125
Nov-06-09Initiated Jefferies & Co Buy $130
Jul-17-09Initiated Soleil Buy $91
Sep-26-07Initiated Banc of America Sec Buy $110
Feb-23-07Downgrade Robert W. Baird Outperform → Neutral $83 → $76
Jul-30-21 10:22AM  
01:32AM  
Jul-29-21 05:35PM  
04:15PM  
Jul-27-21 12:27PM  
06:30AM  
Jul-23-21 07:01AM  
Jul-22-21 03:03PM  
Jul-21-21 05:59AM  
Jul-14-21 04:15PM  
Jul-06-21 10:59AM  
Jun-30-21 05:00PM  
Jun-24-21 04:48PM  
Jun-21-21 11:51AM  
08:00AM  
Jun-18-21 09:58AM  
May-29-21 04:11PM  
May-20-21 08:30AM  
May-10-21 05:13PM  
11:11AM  
Apr-30-21 09:29AM  
05:31AM  
02:19AM  
Apr-29-21 05:45PM  
04:15PM  
Apr-28-21 05:32PM  
Apr-26-21 08:09AM  
Apr-22-21 12:33PM  
Apr-15-21 08:30AM  
Apr-13-21 09:36AM  
Apr-05-21 08:37AM  
Apr-01-21 09:18AM  
Mar-29-21 03:44PM  
Mar-26-21 12:24PM  
08:16AM  
Mar-22-21 06:18PM  
Mar-15-21 07:31AM  
Mar-13-21 11:30AM  
Mar-11-21 10:45AM  
Mar-05-21 04:16PM  
Feb-22-21 04:15PM  
Feb-12-21 09:19AM  
05:31AM  
05:29AM  
Feb-11-21 05:45PM  
04:52PM  
04:20PM  
Feb-10-21 10:30AM  
09:12AM  
Feb-08-21 09:51AM  
Feb-05-21 09:53AM  
Feb-04-21 04:10PM  
Jan-25-21 04:15PM  
Jan-21-21 08:00AM  
Jan-10-21 10:51AM  
Jan-08-21 08:30AM  
Dec-21-20 01:20PM  
09:54AM  
Dec-14-20 07:17PM  
Dec-11-20 08:11AM  
Dec-10-20 05:33PM  
Dec-04-20 08:45AM  
Dec-02-20 11:08AM  
Nov-27-20 09:21AM  
Nov-19-20 11:30AM  
Nov-13-20 09:08AM  
Nov-11-20 12:19PM  
Nov-09-20 10:39AM  
Nov-04-20 12:20PM  
Oct-30-20 10:45AM  
04:31AM  
Oct-29-20 05:45PM  
04:59PM  
04:15PM  
Oct-28-20 04:36PM  
12:41PM  
09:53AM  
Oct-26-20 12:25PM  
Oct-24-20 08:35AM  
Oct-23-20 08:44AM  
Oct-22-20 12:33PM  
Oct-19-20 08:30AM  
Oct-12-20 02:53PM  
09:53AM  
Sep-25-20 01:52PM  
Sep-21-20 09:56AM  
Sep-14-20 09:46AM  
Sep-02-20 07:47AM  
Aug-31-20 12:54PM  
Aug-29-20 11:31AM  
Aug-24-20 11:35AM  
Aug-17-20 11:46AM  
Aug-10-20 08:31AM  
Aug-07-20 12:20PM  
10:23AM  
Aug-04-20 08:30AM  
Jul-31-20 08:33PM  
10:36AM  
Jul-30-20 05:45PM  
04:15PM  
Bio-Rad Laboratories, Inc. develops, manufactures, and markets life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
RAMALINGAM AJITSVP, Chief Accounting OfficerApr 29Option Exercise0.002760318May 03 01:48 PM
Last Andrew J.EVP, Chief Operating OfficerApr 29Option Exercise0.001,00001,734Apr 30 02:31 PM
Daskal IlanEVP, Chief Financial OfficerApr 08Option Exercise0.0070001,157Apr 09 11:38 AM
ERNST TIMOTHY SEVP, General Counsel & SecFeb 19Option Exercise159.3240063,7282,143Feb 22 04:05 PM
ERNST TIMOTHY SEVP, General Counsel & SecFeb 19Sale640.77923591,4991,220Feb 22 04:05 PM
WRIGHT DARAExecutive Vice PresidentDec 16Option Exercise0.005020502Dec 17 04:34 PM
Crowley MichaelEVP, GBL Commercial OperationsDec 15Sale580.67374217,1713,669Dec 17 12:54 PM
TUMOLO ANNETTEExecutive Vice PresidentNov 06Option Exercise159.321,200191,1845,322Nov 10 12:40 PM
TUMOLO ANNETTEExecutive Vice PresidentNov 06Sale640.721,200768,8654,122Nov 10 12:40 PM
SCHWARTZ NORMAN DChairman, President, and CEOSep 11Option Exercise0.003,2000299,834Sep 15 02:13 PM
HUTTON RONALD WVice President and TreasurerSep 11Option Exercise0.0015004,740Sep 14 06:59 PM
TUMOLO ANNETTEExecutive Vice PresidentSep 11Option Exercise0.0060004,420Sep 14 06:55 PM
Crowley MichaelEVP, GBL Commercial OperationsSep 11Option Exercise0.0060004,341Sep 14 06:50 PM
Magni GiovanniEVP, Chief Strategy OfficerSep 11Option Exercise69.781,00069,78022,743Sep 14 11:42 AM
Magni GiovanniEVP, Chief Strategy OfficerSep 10Option Exercise259.111,771458,88222,410Sep 14 11:42 AM
Magni GiovanniEVP, Chief Strategy OfficerSep 08Option Exercise0.00400021,829Sep 09 01:48 PM
SCHWARTZ NORMAN DChairman, President, and CEOSep 07Option Exercise0.003,0000298,122Sep 09 02:53 PM
ERNST TIMOTHY SEVP, General Counsel & SecSep 07Option Exercise0.0050001,960Sep 09 02:00 PM
HUTTON RONALD WVice President and TreasurerSep 07Option Exercise0.0017004,649Sep 09 01:57 PM
Crowley MichaelEVP, GBL Commercial OperationsSep 07Option Exercise0.0060004,039Sep 09 01:56 PM
TUMOLO ANNETTEExecutive Vice PresidentSep 07Option Exercise0.0060004,118Sep 09 01:44 PM
TUMOLO ANNETTEExecutive Vice PresidentSep 05Option Exercise0.0060003,765Sep 09 01:44 PM
Magni GiovanniEVP, Chief Strategy OfficerSep 05Option Exercise0.00500021,677Sep 09 01:46 PM
Crowley MichaelEVP, GBL Commercial OperationsSep 05Option Exercise0.0060003,665Sep 09 01:56 PM
HUTTON RONALD WVice President and TreasurerSep 05Option Exercise0.0018004,542Sep 09 01:57 PM
ERNST TIMOTHY SEVP, General Counsel & SecSep 05Option Exercise0.0050001,633Sep 09 02:00 PM
SCHWARTZ NORMAN DChairman, President, and CEOSep 05Option Exercise0.002,6000420,261Sep 09 02:53 PM
SCHWARTZ NORMAN DChairman, President, and CEOSep 04Option Exercise0.002,6000418,951Sep 09 02:53 PM
ERNST TIMOTHY SEVP, General Counsel & SecSep 04Option Exercise0.0050001,306Sep 09 02:00 PM
HUTTON RONALD WVice President and TreasurerSep 04Option Exercise0.0018004,425Sep 09 01:57 PM
Crowley MichaelEVP, GBL Commercial OperationsSep 04Option Exercise0.0060003,273Sep 09 01:56 PM
Magni GiovanniEVP, Chief Strategy OfficerSep 04Option Exercise0.00500021,425Sep 09 01:46 PM
TUMOLO ANNETTEExecutive Vice PresidentSep 04Option Exercise0.0060003,373Sep 09 01:44 PM
ERNST TIMOTHY SEVP, General Counsel & SecSep 03Option Exercise0.004640967Sep 08 01:09 PM
HUTTON RONALD WVice President and TreasurerSep 03Option Exercise0.0015404,299Sep 08 12:43 PM
Crowley MichaelEVP, GBL Commercial OperationsSep 03Option Exercise0.0055602,866Sep 08 12:32 PM
TUMOLO ANNETTEExecutive Vice PresidentSep 03Option Exercise0.0055602,966Sep 08 01:00 PM
Magni GiovanniEVP, Chief Strategy OfficerSep 03Option Exercise0.00371021,109Sep 08 12:51 PM
SCHWARTZ NORMAN DChairman, President and CEOSep 03Option Exercise0.002,3190417,501Sep 08 03:20 PM
Magni GiovanniEVP, Chief Strategy OfficerAug 19Option Exercise121.5921,1502,571,56433,585Aug 21 02:01 PM
Magni GiovanniEVP, Chief Strategy OfficerAug 19Sale519.8812,8476,678,84420,738Aug 21 02:01 PM
Magni GiovanniEVP, Chief Strategy OfficerAug 18Sale518.812,3821,235,80512,435Aug 19 12:42 PM